published meta-analysis   sensitivity analysis   studies

amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias recoverydetailed resultsACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32] 1.08[0.88; 1.32]ACTIV-3 (BRII-196 and BRII-198), 202110%354NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-29 12:32 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 887 - roots T: 290